Market Expansion of Fecal Occult Blood and Urine Testing Products in Overseas Markets
First written in FY2016. 28 of 37 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-07-30.
The whole theme swung hardest in 2017: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- 2026-07-30AdvancedEarnings
「Overseas sales of fecal occult blood testing reagents increased, supporting growth in overseas revenue.」
Increased sales of fecal occult blood testing reagents in overseas markets were reported as progress in overseas revenue. - FY2026AdvancedAnnual report
「The Group will make fecal occult blood testing (FIT) its core overseas business and steadily capture growth in testing demand, including through an increase in the number of countries adopting FIT and expansion of the eligible age range for colorectal cancer screening in various countries. It will also seek to maximize demand through proactive market development and deeper collaboration with existing distributors.」
The company clearly identified FIT as the core of its overseas expansion and translated this into an execution policy combining expansion into new adopting countries, broader eligible screening ages, market development and collaboration with existing distributors. - FY2026-H1AdvancedAnnual report
「Revenue for the six months ended during the current consolidated interim accounting period was ¥20,430 million, up 3.6% year on year, due to increased overseas sales of fecal occult blood testing reagents and equipment. Overseas sales were ¥5,449 million, up 11.3% year on year.」
Sales of fecal occult blood testing reagents and equipment grew in overseas markets, lifting overseas sales 11.3% year on year to ¥5,449 million. - FY2025AdvancedAnnual report
「Overseas sales were ¥10,710 million, up 5.9% year on year, as sales of both urinalysis reagents and fecal occult blood testing reagents grew.」
Sales of both fecal occult blood and urinalysis products grew overseas, resulting in a 5.9% year-on-year recovery in overseas sales. - FY2025-H1Decline in overseas fecal occult blood productsAnnual report
「Overseas sales were ¥4,898 million, up strongly on sales of urinalysis reagents but down 6.4% year on year due to lower sales of fecal occult blood testing reagents.」
In overseas markets, urinalysis reagent sales grew strongly, but fecal occult blood testing reagent sales declined, resulting in a 6.4% year-on-year decline in overseas sales. - FY2024-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥7,696 million, up 16.8% year on year.」
Sales of fecal occult blood testing reagents in overseas markets increased substantially, lifting overseas sales 16.8% year on year. - FY2024-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥5,233 million, up 18.6% year on year.」
Sales of fecal occult blood testing reagents in overseas markets rose 18.6% year on year, reflecting progress in overseas market expansion. - FY2024-Q1AdvancedAnnual report
「Overseas revenue increased as sales of fecal occult blood testing reagents rose following the resolution of the impact of inventory adjustments, despite a decline in sales of urinalysis reagents, reaching ¥2,523 million, up 12.3% year on year.」
In overseas markets, urinalysis reagent sales declined, while fecal occult blood testing reagent sales increased as the impact of inventory adjustments subsided, leading to a recovery in overseas sales. - FY2023-Q3Decline in overseas fecal occult blood products due to inventory adjustmentsAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined because inventories were increased in preparation for the resumption of screening programs and subsequently adjusted, resulting in revenue of ¥6,587 million, down 1.1% year on year.」
Sales of fecal occult blood testing products in overseas markets were affected by inventory adjustments following an increase in inventories ahead of the resumption of screening programs. - FY2023-Q2RestatedAnnual report
「Overseas revenue increased for urinalysis reagents, but sales of fecal occult blood testing reagents declined, resulting in revenue of ¥4,412 million, down 4.9% year on year.」
The increase in urinalysis reagents in overseas markets was insufficient to offset the decline in fecal occult blood testing reagents, resulting in lower overseas sales. - FY2023-Q1Decline in overseas fecal occult blood productsAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined, resulting in revenue of ¥2,246 million, down 4.0% year on year.」
In overseas markets, sales of urinalysis products increased, but fecal occult blood testing reagents and equipment declined, resulting in lower overseas sales. - FY2022AdvancedAnnual report
「Colorectal cancer screening programs in various regions that had been suspended due to the spread of COVID-19 resumed. The company promoted demand generation as web-based screening, mail-in screening, pharmacy-based screening and endoscopy triage gained wider acceptance. For overseas sales of urinalysis reagents and equipment, the company sought to expand sales through collaboration with SYSMEX CORPORATION.」
In addition to the resumption of colorectal cancer screening in various regions, the company pursued demand generation through web-based, mail-in and pharmacy-based screening and endoscopy triage, and sought to expand overseas sales of urinalysis products through collaboration with SYSMEX CORPORATION. - FY2022-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥6,660 million, up 41.3% year on year.」
Screening programs resumed in various overseas markets, lifting sales of fecal occult blood testing reagents and equipment 41.3% year on year to ¥6,660 million. - FY2022-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers following the resumption of national screening programs, reaching ¥4,637 million, up 60.1% year on year.」
With screening programs resuming in various countries, sales of fecal occult blood testing reagents and equipment in overseas markets rose 60.1% year on year to ¥4,637 million. - FY2022-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥2,339 million, up 46.5% year on year.」
Sales of fecal occult blood testing reagents and equipment in overseas markets rose 46.5% year on year to ¥2,339 million. - FY2021-Q3Slower overseas expansion due to the COVID-19 pandemicAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥4,712 million, down 10.1% year on year.」
The increase in urinalysis products in overseas markets was insufficient to offset the decline in fecal occult blood testing products, resulting in a 10.1% year-on-year decline in overseas sales. - FY2021-Q2Slower overseas expansion due to the COVID-19 pandemicAnnual report
「Overseas revenue increased for urinalysis reagents and analyzers, but sales of fecal occult blood testing reagents and analyzers declined as participation in national screening programs decreased or programs were suspended, resulting in revenue of ¥2,897 million, down 17.7% year on year.」
Overseas sales fell 17.7% year on year as fecal occult blood testing reagents and equipment were affected by lower participation in, and interruptions to, screening programs. - FY2021-Q1Slower overseas expansion due to the COVID-19 pandemicAnnual report
「Overseas sales were ¥1,596 million, down 11.5% year on year. Sales of urinalysis reagents and equipment increased, but sales of fecal occult blood testing reagents and equipment declined due to lower participation in, and interruptions to, screening programs.」
In overseas markets, sales of urinalysis products increased, but sales of fecal occult blood testing reagents and equipment declined due to lower participation in, and interruptions to, screening programs, resulting in an 11.5% year-on-year decline in overseas sales. - FY2020AdvancedAnnual report
「Overseas sales were ¥7,040 million, up 16.0% year on year, as sales of urinalysis reagents and equipment and fecal occult blood testing reagents grew substantially.」
Overseas sales of urinalysis reagents and equipment and fecal occult blood testing reagents rose 16.0% year on year to ¥7,040 million. - FY2020-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥5,242 million, up 24.6% year on year.」
Sales of both fecal occult blood testing reagents and urinalysis reagents and equipment grew in overseas markets, lifting overseas sales 24.6% year on year to ¥5,242 million. - FY2020-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥3,520 million, up 31.1% year on year.」
Both fecal occult blood testing reagents and urinalysis reagents and equipment grew in overseas markets, lifting overseas sales 31.1% year on year. - FY2020-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and urinalysis reagents and analyzers, reaching ¥1,803 million, up 35.1% year on year.」
Both fecal occult blood testing reagents and urinalysis reagents and equipment grew in overseas markets, lifting overseas sales 35.1% year on year to ¥1,803 million. - FY2019AdvancedAnnual report
「Overseas sales were ¥6,070 million, up 12.3% year on year, driven by strong growth in sales of fecal occult blood testing reagents.」
Full-year overseas sales of fecal occult blood testing reagents rose 12.3% year on year to ¥6,070 million. - FY2019-Q3AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥4,208 million, up 9.6% year on year.」
Sales of fecal occult blood testing reagents in overseas markets grew, lifting overseas sales 9.6% year on year to ¥4,208 million. - FY2019-Q2AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents, reaching ¥2,685 million, up 9.0% year on year.」
Sales of fecal occult blood testing reagents in overseas markets grew, lifting overseas sales 9.0% year on year to ¥2,685 million. - FY2019-Q1AdvancedAnnual report
「Overseas revenue increased substantially on growth in sales of fecal occult blood testing reagents and analyzers, reaching ¥1,335 million, up 12.6% year on year.」
Sales of fecal occult blood testing products in overseas markets grew, lifting overseas sales 12.6% year on year to ¥1,335 million. By contrast, sales of urinalysis equipment overseas declined. - FY2018AdvancedAnnual report
「Overseas sales were ¥5,405 million, up 32.3% year on year, as sales of fecal occult blood testing reagents and urinalysis reagents and equipment grew substantially.」
Both fecal occult blood products and urinalysis products and equipment grew, lifting overseas sales 32.3% year on year to ¥5,405 million. - FY2018-Q3AdvancedAnnual report
「Overseas sales were ¥3,838 million, up 33.6% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
Both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew, lifting overseas sales 33.6% year on year to ¥3,838 million. - FY2018-Q2AdvancedAnnual report
「Overseas sales were ¥2,464 million, up 32.3% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
Both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew, lifting overseas sales 32.3% year on year to ¥2,464 million. - FY2018-Q1AdvancedAnnual report
「Overseas sales were ¥1,185 million, up 65.8% year on year, as sales of both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew substantially.」
Both fecal occult blood testing reagents and equipment and urinalysis reagents and equipment grew, lifting overseas sales 65.8% year on year to ¥1,185 million. - FY2017AdvancedAnnual report
「Overseas sales were ¥4,086 million, up 16.8% from the previous fiscal year, as sales of urinalysis reagents and equipment grew despite sluggish sales of fecal occult blood testing reagents.」
For the full fiscal year, overseas sales rose 16.8% from the previous fiscal year to ¥4,086 million, driven by growth in urinalysis reagents and equipment despite sluggish fecal occult blood products. - FY2017-Q3AdvancedAnnual report
「Overseas sales were ¥2,873 million, up 16.8% year on year, as growth in urinalysis reagents and equipment offset sluggish sales of fecal occult blood testing reagents.」
While fecal occult blood testing products remained sluggish, overseas sales rose 16.8% year on year on growth in urinalysis reagents and equipment. - FY2017-Q2AdvancedAnnual report
「Overseas sales were ¥1,862 million, up 6.0% year on year, as growth in urinalysis reagents and equipment outweighed sluggish sales of fecal occult blood testing reagents and equipment.」
While fecal occult blood products remained sluggish, urinalysis reagents and equipment grew, lifting overseas sales 6.0% year on year. - FY2017-Q1RestatedAnnual report
「We continued to focus on expanding adoption of fecal occult blood testing reagents and equipment in the United States, while pursuing national colorectal cancer screening programs in Europe, particularly in England. In June 2016, the U.S. Preventive Services Task Force (USPSTF) issued new guidelines on colorectal cancer screening in the United States.」
For fecal occult blood testing products, the company continued efforts to expand adoption in the United States and secure national screening programs in Europe. - FY2016First statedAnnual report
「Colorectal cancer screening tests adopted in the previous fiscal year by the French government and by Madrid and Barcelona in Spain made a significant contribution to sales. We also focused on expanding fecal occult blood testing reagents and equipment in North America and Asia, and on increasing sales of urinalysis reagents and equipment in Italy.」
The company is expanding its fecal occult blood and urinalysis products overseas, starting with colorectal cancer screening.